• In an October 2023 lecture, David E. Martin, Ph.D., detailed how we can know that SARS-CoV-2 is a manmade bioweapon that has been in the works for 58 years
• The virus called “coronavirus” was first described in 1965. Two years later, the U.S. and U.K. launched an exchange program where healthy British military personnel were infected with coronavirus pathogens from the U.S. as part of the U.S. biological weapons program
• In 1992, Ralph Baric at University of North Carolina, Chapel Hill, took a pathogen that used to infect the gut and lungs and altered it with a chimera to make it infect the heart, causing cardiomyopathy. This research was part of the efforts to produce an HIV vaccine
• In November 2000, Pfizer patented its first spike protein vaccine. Between 2000 and 2019, vaccine trials using this technology proved it was lethal, yet in the summer of 2020, the clinical trials for the SARS-CoV-2 shots went straight into human trials
• mRNA spike protein was publicly described as a bioweapon 18 years ago. In 2005, at a conference hosted by DARPA and The Mitre Corporation, the mRNA spike protein was hailed as a “biological warfare-enabling technology,” i.e., a biological warfare agent

(Mercola)—The video above features a lecture David E. Martin,¹ Ph.D., gave in Dornach, Switzerland, in late October 2023. Martin is a national intelligence analyst and founder of IQ100 Index, which developed linguistic genomics, a platform capable of determining the intent of communications.

This technology has allowed Martin to scan and review millions of patents, resulting in a paper trail^2,3 that conclusively proves SARS-CoV-2 is a man made bioweapon that has been in the works for 58 years.

Unambiguous Admission of a Premeditated Plandemic

As he is now in the habit of doing, Martin opens his lecture with a quote by Peter Daszak, president of EcoHealth Alliance. During a March 27, 2015, forum on Medical and Public Health Preparedness for Catastrophic Events, Daszak noted⁴ that unless an infectious disease crisis is at an emergency threshold, it tends to be ignored.

“To sustain the funding base beyond the crisis, we need to increase public understanding of the need for MCMs (medical countermeasures) such as a pan-influenza or pan-coronavirus vaccine,” Daszak said, adding:⁵

“A key driver is the media, and the economics follow the hype. We need to use that hype to our advantage to get to the real issues. Investors will respond if they see profit at the end of the process.”

Rest of the story here.